Estradiol-intranasal: a review of its use in the management of menopause.

@article{Dooley2001EstradiolintranasalAR,
  title={Estradiol-intranasal: a review of its use in the management of menopause.},
  author={Mukta Dooley and Caroline M. Spencer and Douglas Ormrod},
  journal={Drugs},
  year={2001},
  volume={61 15},
  pages={
          2243-62
        }
}
UNLABELLED Estradiol-intranasal is a nasal spray formulation containing an aqueous solution of 17beta-estradiol that has a unique pulse-like pharmacokinetic profile. In a well designed, placebo-controlled trial estradiol-intranasal 200 to 400 microg/day significantly reduced the incidence and severity of climacteric symptoms in women with moderate to severe menopausal symptoms after 4 and 12 weeks' treatment. The efficacy of estradiol-intranasal 300 microg/day was similar to that of oral… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Hormone exposure and effects on follical - stimulating hormone ( FSH ) after nasal ad - monistration of estradiol in postmenopausal women [ abstract no . S 21 ]

  • C Laveille, Y Tsouderos, C Varin
  • Gynecol Endocrinol
  • 2001

SloughUK . Prescribing information . Aerodiol [ online ] Aerodiol Rm

  • HermensWA, CW Belder, JM Merkus
  • British National Formulary
  • 2001

Comparison of intranasal and transdermal 17 β - estradiol on bone loss in post - menopausal women at 1 year [ abstract ]

  • P Garnero, C Ribot, B Pornel
  • Maturitas
  • 2000

Effects of estrogen on cognition , mood , and cerebral blood flow in AD : a controlled study

  • RA Mulnard, CW Cotman, C Kawas
  • Neurology
  • 2000

Similar Papers

Loading similar papers…